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Abstract 
As small molecule drugs become harder to develop and less cost effective for patient use, efficient 
strategies for their property improvement become increasingly important to global health initiatives. 
Improvements in the physical properties of Active Pharmaceutical Ingredients (APIs), without changes 
in the covalent chemistry, have long been possible through the application of binary component 
solids. This was first achieved through the use of pharmaceutical salts, within the last 10-15 years 
with cocrystals and more recently coamorphous systems have also been consciously applied to this 
problem. In order to rationally discover the best multicomponent phase for drug development, 
intermolecular interactions need to be considered at all stages of the process. This review highlights 
the current thinking in this area and the state of the art in: pharmaceutical multicomponent phase 
design, the intermolecular interactions in these phases, the implications of these interactions on the 
material properties and the pharmacokinetics in a patient.  
Key words 
Pharmaceutical; Cocrystal; Salt; Intermolecular interactions; multicomponent crystals; 
Physicochemical properties; Bioavailability; Pharmacokinetics 
 
1. Introduction 
In the making of new medicines, it is important to optimise and control the quantity of an active drug 
which is delivered to the body, organ system, or tissue in question. Appropriate quality is achieved by 
strict control of the manufacturing route of the medicine, to meet its designated attributes, and the 
solid state chemistry of the drug molecule. This is done in order to ensure reproducible delivery of the 
drug to the right place at the right time to treat the disease. Alterations to the solid-state chemistry of 
drug molecules are common within the pharmaceutical industry as they enable modification of the 
physical properties of a drug, without changing the pharmacology of the active pharmaceutical 
ingredient (API) through modification of covalent bonds. Addition of second components to alter the 
APIs physical chemistry has been commonplace within the pharmaceutical industry for well over a 
quarter of a century in the form of pharmaceutical salts.[1] More recently, i.e. for around a decade,[2] 
it has also been common practice to include pharmaceutical cocrystals in the search for the optimum 
properties.[3-7] There have been many excellent reviews on the intermolecular interactions,[8] 
growth,[9] manufacture[10] and utility of cocrystals in this time,[11-13] along with significant advances 
to accompany them. There has been seeming reticence within the industry to turn the potential of 
cocrystals into products however. This issue has been partially blamed on a number of key perceived 
problems: regulatory uncertainty, problems with manufacture at scale and a lack of in vivo 
confirmation of the promise of these systems in the lab.[14] This review will address these points from 
the perspectives of the intermolecular interactions within these phases, their properties pertinent to 
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manufacture and their in vivo pharmacokinetics. Although not the focus of this review it is of note that 
recently the regulatory opinion of cocrystals has changed in the eyes of the FDA.[15] It is also 
important that the EMA[16] see the utility of these phases as their defining trait. With this in mind this 
review will focus on the following areas; intermolecular interactions, their implications on design 
towards robust manufacturing and their pharmacokinetics.   
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2. Intermolecular interactions in multicomponent crystals 
2.1 Classification of multicomponent crystals 
In the pharmaceutical context the basis of the utility of cocrystals and salts lies in the alterations they 
impart on the intermolecular interactions within the crystalline state and their potential to change in 
vivo solution behaviour through altered dissolution. Both cocrystals and salts have been seen to 
improve many manufacturing and biopharmaceutical properties within API materials, so knowledge of 
which characteristics to seek, using what chemical design strategy, is of great utility to the 
pharmaceutical industry and the patients it serves. It is commonly accepted that the bonding 
behaviours within salts and cocrystals lie along similar, though different, chemistry, but a specific 
tension is added within the confines of the pharmaceutical sector due to regulatory necessity. It has 
been suggested that cocrystals and salts offer new intellectual property opportunities.[17] Filing a 
patent requires some degree of definition of the disclosed phase however, as does the need to submit 
information about a new phase to regulatory agencies.[15, 16] This inherently drives an agenda which 
is sometimes more prescriptive, in terms of defining the nature of the phase, than the chemistry which 
controls it. Initially there was reticence to see salts and cocrystals as part of the same continuum,[18] 
but that has changed over the last decade as more data has emerged. Recently a Venn diagram 
approach has been proposed by de Gelder and co-workers to describe the differing phases and can 
be seen in Figure 1 (although the solid / liquid at 293.15 K, 10
5
Pa distinction between solvents and 
coformers represents a chemically arbitrary division).[19]  
 
Figure 1. de Gelder and co-workers’ Proposed classification system for pharmaceutical solid forms. 
From reference [19] with permission.  
This depiction of bonding behaviours is a progression from the cartoon depiction of the solid form 
chemistry that has previously been used to describe these phases[12]. A version of such a cartoon 
can be seen in Figure 2. Here it is also evident that significant crossover is possible within cocrystal 
and salts. As it is clear that understanding the molecular level architectures within API phases are 
essential for appropriate form designation, section 2.2 will focus on examples of the relevant 
interactions. It also follows that without discovery of novel phases there is nothing to define, so this 
section will also deal with molecular level design strategies for the discovery of new drug phases 
(section 2.3) before discussion of property based design. 
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Figure 2. Possible form options for an API. A and B are polymorphs of the API (forms C to H are also 
potentially capable of forming polymorphs), C is a stoichiometric solvate/hydrate (can possess 
charge), D a classic salt, E a molecular cocrystal (conceptually identical to C), F an ionic cocrystal, G 
is a solid solution (mixed crystal), H is a potentially non-stoichiometric inclusion compound e.g. a 
channel hydrate and I is an amorphous form of the pure API, there is also potential to make forms D 
to F amorphous (Adapted from reference[12]). 
2.2 Understanding Intermolecular interactions within salts and cocrystals 
In order for any multicomponent crystal to form there must be some kind of interaction between the 
molecules or ions that make up the crystal. For the system to be thought of as multi-component (i.e. a 
cocrystal or salt of any of the types shown in Figure 2 C to H) such interactions are of a non-covalent 
and hence supramolecular type. While the energy and geometry of the interactions between two 
isolated (gas phase) molecules are relatively amenable to calculation and hence relatively well 
understood, the three dimensional, close-packed nature in crystals makes understanding the ways in 
which they are held together considerably more challenging. Ultimately, computational crystal 
structure prediction (CSP) methods may well hold the key to a holistic understanding of the full 
spectrum of intermolecular interactions in crystals. Indeed it is only through a full understanding of the 
contribution to the overall stability of all of the long and short range contacts made by a given 
molecule in a crystal that it will be ultimately possible to reliably predict the most stable crystal 
structure. Even then, nucleation and growth considerations may mean that the most stable structure 
is not experimentally accessible and hence an understanding of intermolecular interactions at all 
stages along the crystal formation pathway is really what is required. Such information remains 
beyond the scope of even the very powerful CSP methods currently available[20] although it is 
noteworthy that recent Cambridge Blind Tests have produced some remarkable successes.[21] In the 
case of multi-component systems the CSP challenge is even more daunting because of the additional 
degrees of freedom and hence possible structures enabled by the presence of a second 
component[22] and in practical terms the understanding of multi-component crystals is often based on 
empirical data gathering and rationalisation. However, experience in common association modes 
coupled with empirical rules[23-25] and carefully targeted calculations can give insight into likely 
cocrystal and salt formation. A good example is the deliberate engineering of ternary (three-
component) cocrystals based on observations of the best hydrogen bond donor/best acceptor 
pairings.[26] More recently a combined understanding of pKa values, hydrogen bond basicity (-
values), and supramolecular synthon history has been used to engineer further ternary cocrystal 
systems as in acridine·3-hydroxybenzoic acid· 2-amino-4,6-dimethylpyrimidine, Figure 3.[27]  
A B C
D
HG
F
I
API molecule with acceptor 
and donor H-bond potential
Solvent/water molecule with 
acceptor and donor H-bond 
potential
API Cation/Salt counterion
Structurally homologous 
molecule for solid solution
Coformer molecule usually with 
acceptor and donor H-bond 
potential
E
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Figure 3. ternary cocrystal of acridine·3-hydroxybenzoic acid· 2-amino-4,6-dimethylpyrimidine  
prepared by careful balancing of pKa values, -values, and supramolecular synthon history 
(reproduced with permission from reference [27]). 
2.3 The Supramolecular Synthon Approach 
The supramolecular synthon approach[28] looks for frequently occurring and hence reproducible 
patterns of intermolecular interactions in order to identify building block type motifs that can be used 
to design and ‘engineer’ a crystal or cocrystal structure. Such interactions may be easily recognized 
like the well-defined carboxylic acid dimer[29] or amide NH···O hydrogen bonding motifs, or they may 
be interactions such as -stacking, interactions between aliphatic chains or halogen bonding motifs, 
Figure 4.  
 
Figure 4.  Common supramolecular synthons – interactions between functional groups on different 
molecules in crystals that can sometimes be used in a predictive fashion to engineer crystal and 
cocrystal structures. 
The supramolecular synthon approach has been used with considerable success in the production of 
cocrystals, for example the use of the pyridine – carboxylic acid synthon in designing cocrystals of the 
anti-tuberculosis drug isoniazid, Figure 5.[30] A synthon-based crystal engineering approach has 
been used to design glutamic acid cocrystals for the poorly soluble sodium channel blocker 2-[4-(4-
chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide, resulting in dramatic solubility 
enhancement.[31]  While the geometry of the pyridine-carboxylic acid synthon is expected to be quite 
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similar in both neutral and (proton transferred) salt form, in fact the calculated energy of such 
cocrystals and hence the predicted cocrystal form landscape, is found to be highly sensitive to the 
proton position.[32] The supramolecular synthon approach is quite useful in predicting the likelihood 
of cocrystal formation over competing self-sorting of the two components. For example a Cambridge 
Structural Database[33] analysis showed that the formation of hydroxyl···pyridine supramolecular 
heterosynthon in crystal structures that contain hydroxyl and pyridine moieties in the absence of other 
hydrogen-bonding moieties is near-certain, implying that the heterosynthon and others like it such as 
the hydroxyl···cyano heterosynthon, are strongly favoured over the competing hydroxyl···hydroxyl 
supramolecular homosynthon, giving rise to a synthon hierarchy.[34]  
 
Figure 5. Sheet structure of Form 2 isoniazid·vanillic acid assembled via N−H···O, O−H···N hydrogen 
bonds, and the acid···pyridine supramolecular heterosynthon (reproduced with permission from ref. 
[30]) 
 
2.4 Ionic interactions - Salt vs. Cocrystal Formation 
Transfer of a proton in solution carries little steric consequence because of the proton’s small size and 
hence the protonation of a base by an acid (commonly an amine or nitrogen heterocyclic base by a 
mineral or carboxylic acid, for example[35]) is governed solely by well understood electronic factors in 
combination with the solvation properties of the acid, base and the resulting salt. These factors are 
reflected in the thermodynamic pKa values of the acid and the conjugate acid of the base and 
represent their Brønsted acidity. The pKa represents the pH at which the solubilised population’s 
ionisable group or groups are 50% charged and 50% protonated and is dependent on the acid/base 
strength of the molecule. Strictly speaking bases should be defined by their pKb, but this is seldom 
used in practice. So if a molecule has a pKa of 11 analysis of the structure to determine whether a 
weak acid or strong base is being described would be necessary.[1] This concept of salt and cocrystal 
formation is dealt with in more depth in section 3 where the design of salts and cocrystals in solution 
is considered. From the pKa the equilibrium concentration of ions can be calculated and if the pKa 
difference between acid and the protonated base is more than 2-3 log units then proton transfer is 
essentially complete. Similarly, for a given solid state reaction this pKa rule generally holds true and 
salt formation is expected,[36] although recent theoretical and high pressure studies have shown that 
proton transfer in the pyridine-formic acid system is dependent on the amount of formic acid 
present.[37, 38] Ions are charged and interact strongly with polar molecules, particularly water, and 
hence salts are often highly hygroscopic, especially when the anion is a conjugate base of a strong 
acid such as sulfate, hydrogen phosphate or chloride, for example. In terms of intermolecular 
interactions the situation is fairly easy to rationalise, at least in broad terms. While the salt is often 
held together by strong charge-assisted hydrogen bonding interactions, such as the –NH3
+
OSO3H
–
 
hydrogen bonding in clopidogrel hydrogen sulfate (Figure 6),[39] this single hydrogen bonding 
interaction frequently leaves much of one or more of the ions with exposed polar functionality. This 
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exposed region of charge can be stabilised by additional interactions to water, particularly in the case 
of larger organic cations and anions with a high hydration energy such as sulfate.[40] This is the case 
with the antibacterial trimethoprim sulfate trihydrate, for example.[41] In extreme cases absorption of 
water by the ions results in a highly concentrated salt solution which then acquires more water from 
the atmosphere by osmosis giving rise to the phenomenon of deliquescence. Under these 
circumstances isolation of a stable crystalline salt under ambient temperature and humidity is often 
not possible and the material is unsuitable for drug formulation. Similarly, salts frequently form 
stoichiometric hydrates[42, 43] in which the exposed faces of the component ions are stabilised by 
the incorporation of crystallographically well defined sites containing water. In the case of metal ions 
crystalline hydrates can similarly form in which the water coordinates to exposed faces of the metal 
cation. These species are now more properly termed metal aquo complexes. In the era before their 
structural chemistry was well understood,[44] their identification by water content and elemental 
composition alone meant the metal ion coordination and crystal lattice incorporation by hydrogen 
bonding were not possible to distinguish. If fact, simple empirical formulae can mask extremely 
complex structural chemistry as in the mixed hydrate / butanol solvate of the magnesium salt of 
esomeprazole, which contains both a magnesium hexaquo ion, magnesium tris(esomeprazole-H) 
anions containing deprotonated esomeprazole as bidentate ligands and molecules of both water and 
butanol hydrogen bonded within the crystal lattice. The overall formula is thus 
[Mg(H2O)6][Mg(esomeprazolate)3]2·6H2O·6BuOH rather than the simplified 
“Mg(esomeprazole)2·4H2O·2BuOH” and all of the components are linked in an extensive hydrogen 
bonded network, Figure 7.[45] The patent literature suggests that the structure of a number of 
commercially important magnesium esomeprazole salts may be similar.[46] Note that just like salts, 
cocrystals can also form hydrates as in a four-component neutral cocrystal of the antitumor prodrug 
temozolomide, namely tris(temozolomide) 3-phenylacrylic acid 4-amino-1H-imidazole-5-carboxamide 
monohydrate,[47] however the neutral nature of the API and coformer residues makes cocrystal 
hydrate formation to give what is, effectively , a ternary cocrystal, rather less common. 
 
Figure 6. Charge assisted NH
+
···O
–
 hydrogen bonding in clopidogrel hydrogensulfate.[39] 
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Figure 7. The complex structure of the mixed aquo complex – crystalline hydrate 
[Mg(H2O)6][Mg(esomeprazolate)3]2·6H2O·6BuOH.[45] Only the crystallographically unique portion of 
the [Mg(esomeprazolate)3]
–
 ions is shown (one third of the ion). 
If there is a pKa difference of less than two units between acidic and basic components then proton 
transfer from acid to base becomes less certain. It is a weakness of chemical nomenclature that the 
difference between a cocrystal and a salt in an acid-base system can come down to the precise 
location of a hydrogen ion. If it is close to the base then the system is a salt; if it remains close to the 
parent acid (even while strongly hydrogen bonded to the base component) it is a cocrystal! The fine 
differences between salt and cocrystal in these cases has been described by Aakeröy.[48] Indeed in 
some cases proton position is temperature dependent and simple warming can, semantically, 
transform a salt into a cocrystal. In some cases such as the urea-phosphoric acid cocrystal (or 
uronium dihydrogen phosphate salt) there exists a window in which the situation is ambiguous when 
the proton is equally shared between the donor and acceptor groups.[49] However, there are clearly 
cases with low pKa difference in which proton transfer does not occur and any multi-component 
crystal is therefore a cocrystal.  
Ionic interactions are typically properties of salts, or salt cocrystals. They are strong but non-
directional, resulting in close packed ionic solids such as NaCl. Commonly in pharmaceutical salts 
ionic interactions act in concert with hydrogen bonding or coordination interactions and can involve 
charge-assisted hydrogen bonding (Figure 6; an interaction sometimes termed a “salt bridge” in 
protein chemistry) or direct coordination of an anionic residue to a metal cation as in the complex 
anions in magnesium esomeprazole (Figure 7). Ions may also be solvent separated as in the 
antioxidant sodium 5'-O-phosphonopyridoxylidenerhodanine hydrate[50] in which the sodium cations 
are fully hydrated and interact with the anions only via second sphere hydrogen bonding. Ionic bonds 
can also involve less specific interactions between organic ion pairs lacking an acidic proton as in 
propantheline cyclamate in which the –NMe(iPr)2
+
 group forms a range of CH···O interactions with the 
cyclohexylsulfamate counter anion (Figure 8). Such weakly interacting salts derived from APIs and 
GRAS materials have been explored as active ionic liquids.[51] 
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Figure 8. Multiple CH···O interactions in the salt propantheline cyclamate.[51] 
 
2.5 Dipolar interactions 
Dipolar interactions in general are relatively weak and, while directional, they are not as obvious or 
readily applied in cocrystal formation as hydrogen bonding (which is a particular type of dipolar 
interaction). Dipolar interactions between carbonyl groups, for example, occur in liquids such as 
acetone and the weaker nature of carbonyl dipolar interactions compared to hydrogen bonds is 
evident in the low boiling point of acetone (56 
o
C) compared to water (100 
o
C). There are relatively 
few cocrystals in which the components only exhibit dipolar interactions without hydrogen bonding 
(one example is the acetone solvate of odyendane, a Congolese folk medicine[52]), however dipolar 
interactions in polymorphs and cocrystals are hugely important in solid state NMR spectroscopic 
techniques since they give information about intermolecular distances and mutual orientation. This 
data can result in direct structure determination either by NMR alone or in combination with 
complementary techniques such as XRPD, giving rise to the emerging area of NMR 
crystallography.[53] 
 
2.6 Hydrogen bonding 
Hydrogen bonding, because if its strength, directionality and ubiquitous occurrence in drug-like 
molecules is by far the most important interaction in cocrystal design and many cocrystals are formed 
between weak acids and weak bases (pKa difference of less than 2 units) and are linked by hydrogen 
bonding. Hydrogen bonds are strong enough to persist in solution and it is not unreasonable to 
suspect solution association of API and coformer before crystallization in some cases, as in the 
carbamazepine· 4-aminobenzoic acid system.[54] In the absence of highly basic moieties salt 
formation can be extremely challenging and cocrystallization becomes an attractive possibility in 
searching for more soluble forms of highly insoluble drugs. One of the greatest solubility 
enhancements seen so far in terms of API/cocrystal maximum in vivo concentration (Cmax) is for the 
tartaric acid cocrystal of the Phosphodiesterase-IV Inhibitor L-883555. Analysis of the pKa values of 
the free base indicate that the most basic nitrogen atom with a pKa of 4.21 (Figure 9) is too weak a 
base to be protonated by tartaric acid (pKa1 2.89) and hence a cocrystal is expected. In fact IR and 
CP-MAS NMR measurements indicated that the tartaric acid exhibits variable incorporation into 
channels within the API structure and that no proton transfer occurs, resulting in a true cocrystal with 
hydrogen bonding to the N-oxide oxygen atom acceptor.[55] 
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Figure 9. Structure and pKa values of L-883555.[55] 
2.7 - Interactions 
-Stacking interactions occur in either an offset face-to-face or edge-to-face geometry in order to 
maximise the interactions between the electron rich and electron deficient regions of the aromatic ring 
quadrupoles. These - interactions are very important in stabilising many cocrystal systems in which 
there is an aromatic ring. Cocrystals of aromatic heterocycles such as caffeine and theophylline with 
benzoic acids are obvious examples, albeit additionally stabilised by hydrogen bonding (Figure 10). 
As an interesting aside the caffeine·benzoic acid cocrystal was calculated to exist but was only 
recently prepared with the help of carefully designed heteroseeding.[56] Eclipsed face-to-face -
stacking is unusual but has been observed in cocrystals of electron rich and electron deficient 
systems. Two of the simplest and most striking are the 1:1 cocrystals of electron rich benzene[57] and 
bis(benzene) chromium(0)[58] with the electron deficient -system of hexafluorobenzene. In both 
systems the aromatic ring planes are directly on top on one another with an interplanar distance of 
around 3.4 Å, Figure 11. 
 
Figure 10. -stacking in the 1:1 cocrystal of caffeine and benzoic acid.[56] 
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Figure 11. Environment of one molecule of C6F6 in its 1:1 cocrystal with bis(benzene) 
chromium(0).[58] 
 
2.8 Ion- interactions 
The interactions of cations such as K
+
 with aromatic rings has long been recognized and is of 
equivalent strength to a hydrogen bond (around 80 kJ mol
-1
).[59] More recently anion- interactions 
have also come under intense scrutiny.[60] Both are found in salts of aromatic compounds and can 
exert a stabilising influence. One of the most appealing is Harrowfield’s “Calixarene Cupped Caesium: 
a  Coordination Conundrum”[61] in which a single Cs
+
 ion sits in the middle of the four aromatic rings 
of a calix[4]arene anion, with Cs···centroid distances of 3.57 Å, topped by a single molecule of 
acetonitrile, Figure 12. 
 
Figure 12. Cation- interactions stabilise a Cs
+
 ion within the hollow of a calix[4]arene anion.[61] 
 
2.9 Halogen Bonding 
A halogen bond represents a closed shell interaction between the electron deficient -hole opposite a 
covalently bonded halogen atom, particularly in heavier halogens such as iodine and an electron rich 
‘halogen bond acceptor’ such as a pyridine lone pair.[62] Halogen bonding holds together well-known 
entities such as polyiodide anions, I(I2)n
–
, and is used medically in wound treatment by povidone-
iodine (an iodine complex of polyvinylpyrrolidinone).[63] Because of their relatively ‘soft’ nature, 
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halogen bonds do not compete particularly strongly with hydrogen bonds, although they often occur 
simultaneously in structures with both types of chemical functionality. The hydrogen bonded and 
halogen bonded synthons are often orthogonal and hence offer some degree of predictability in 
cocrystal design. Halogen bonds have been used to engineer useful cocrystals of 3-Iodo-2-propynyl-
N-butylcarbamate. This material is used globally as a preservative, fungicide, and algaecide. It is 
difficult to purify and handle because of its sticky nature. Cocrystal formation using either 
alkylammonium iodide to give a salt cocrystal, or bipyridines, results in much more tractable 
pharmaceutical cocrystals (Figure 13).[64] In another halogen bonded cocrystal system an interesting 
stepwise mechanism has been identified for the mechanochemical preparation of halogen bonded 
cocrystals between diiodotetrafluorobenzene and thiomorpholine. The significantly greater strength of 
the I···N halogen bonded synthon over the I···S interaction results in initial formation of a 2:1 cocrystal 
comprising only I···N interactions. Prolonged grinding gives a 1:1 phase with both synthons.[65] 
Halogen bonding between diiodotetrafluorobenzene and iodo-functionalised ureas in combination with 
pyridyl-ureas has also been used to give two-component halogen bonded gels, potentially useful for 
pharmaceutical crystallization.[66] 
 
Figure 13. Supramolecular ribbons formed by orthogonal halogen and hydrogen bonding in the 4,4′-
bipyridine cocrystal with 3-Iodo-2-propynyl-N-butylcarbamate.(reproduced with permission from ref. 
[64]) 
2.10 Closed Shell Interactions 
Along with halogen bonding there exists a range of other closed shell interactions in solids that have 
some crystal engineering potential, particularly aurophilic[67] and the weaker argentophilic 
interactions seen in low oxidation state gold and silver complexes. These are manifest in short 
intermetallic contacts in the solid state structure of these systems and have relativistic origins. A 
lovely example is the dicyanoaurate salt [Mn(1,10-
phenanthroline)2(H2O){Au(CN)2)][Au(CN)2]·0.5EtOH·0.5H2O in which an [Au(CN)2]
–
 ligand bound to 
manganese forms an aurophilic stack with a free dicyanoaurate, Figure 14.  
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Figure 14.  Aurophilic (dotted lines) and -stacking interactions in the structure of 
[Mn(1,10-phenanthroline)2(H2O){Au(CN)2)][Au(CN)2]·0.5EtOH·0.5H2O.[68] 
One final class of closed shell interaction is so-called secondary bonding, popularised particularly by 
Alcock in the 1970’s and 1980’s. Secondary bonding generally occurs between main group atoms and 
heteroatoms in crystalline solids and shares some characteristics with hydrogen bonding, leading to 
some predictability as a supramolecular synthon.[69] An example is Ph2TeO which contains Te···O 
secondary bonds 2.55 Å long.[70] 
 
2.11 van der Waals Interactions and Molecular Shape 
Perhaps one of the most important considerations in cocrystal formation, although one that is difficult 
to understand and control, is molecular shape. In early clathrate chemistry the tendency of ‘awkward’ 
molecular shapes to include solvent or guest molecules and hence form cocrystals was well 
recognised and led to enduringly effective strategies such as the ‘wheel-and-axel’ approach to the 
design of molecules likely to pack poorly and hence form cocrystals.[71] The vast field of calixarene 
chemistry has evolved from the hard-to-pack molecular bowl shape of the calixarenes and hence their 
tendency to crystallise with included guests.[72] Molecular crystals are generally characterised by a 
lack of void space, encompassed in the anthropomorphic Aristotelian adage ‘Nature abhors a 
vacuum’. This close packing arises because van der Waals interactions between molecules are 
ubiquitous and result in a stabilisation according to the contact surface area.[73] Awkwardly shaped, 
non-self-complementary molecules are thus highly likely to incorporate other components present in 
the crystallization medium in order to fill space. This factor is a significant root cause in the 
incorporation of solvent to give solvates. The ubiquitous presence of water in the atmosphere, its 
small size and its ability to form hydrogen bonds means that hydrates are the most common solvates. 
Optimum close packing is sometimes at odds with the formation of strong, directional hydrogen 
bonding interactions and hence some polymorphic systems arise from a trade-off between 
optimization of intermolecular interactions and optimization of close packing. This tension is also 
evident in the formation of crystals with multiple crystallographically independent molecules (Z′ > 
1).[74] A particularly unusual and informative example is the self-included trimesic acid 
5
/6 hydrate. 
This system involves a channel-containing framework comprising layers of trimesic acid and water 
molecules which includes further crystallographically distinct unsolvated trimesic acid in channels 
running throughout the hydrogen bonded structure.[75] This ‘guest’ trimesic acid can be replaced with 
other guests such as picric acid to give a ternary cocrystal of trimesic acid, picric acid and water.[76] 
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The distinct host and guest roles explain the Z′ = 12 structure and the strange 
5
/6 stoichiometry in this 
fully ordered, stoichiometric structure, Figure 15. 
 
Figure 15. Offset layer packing in (trimesic acid·H2O)10·(trimesic acid)2. Trimesic acid molecules A-J 
form a channel-containing framework while K and L are the crystallographically independent guests 
(reproduced with permission from ref. [76]). 
 
3. Molecular level property-based design 
Moving forwards from consideration of the intermolecular interactions a number of factors must be 
considered in order to produce phases that have the optimal pharmaceutical properties. These 
parameters vary from those which are concerned with the robust reproducible manufacture of the 
medicine to those directly associated with its absorption in vivo (solubility and permeability 
behaviours). The following section will deal with the molecular level considerations which enable 
phase design towards these, often competing, end points.  
3.1 Screening for binary compositions 
It is entirely possible that when two solids are combined that there will be no significant interaction. If, 
however the solids of two components are brought together as an intimate mixture and there is an 
interaction, three options are available with respect to their thermodynamic phase behaviours; 
formation of a conglomerate, formation of a binary phase or formation of a solid solution (Figure 16). 
Formation of a conglomerate drives the melting point of each component closer to a central minimal 
value, known as a eutectic, as mole fractions of each component increase. Eutectic compositions 
have been used in pharmaceutical formulations, most notably the local anaesthetic cream EMLA 
(Eutectic Mixture of Local Anaesthetics)[77] and it has been proposed that ‘failed’ cocrystal screens 
could highlight viable eutectic compositions for further development.[78] Due to their complex 
characterisation these phases have seldom been developed for oral medicines to date, however. 
Binary solid compositions in which multiple eutectic points are seen represent the goal of many 
screening activities. Generally the intention of screening is to generate crystalline salts or cocrystals 
with defined stoichiometry, phase stability and melting points above 100°C (for appropriate milling) 
that are readily characterised, as is the hope for polymorphs.[79] The final of the three potential 
thermodynamic outcomes, for a defined interaction, is a solid solution, where the overall melting point 
of the solid is determined by the composition. Such phases seldom follow ideality and it is common to 
represent this by the addition of a dashed line on the phase diagram (such as is seen in Figure 16) as 
there is commonly variability in the experimentally determined melting point for a given composition.  
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Figure 16. Potential binary behaviours that could be seen in screening for a paired set of interacting 
solids. (1) Shows a simple eutectic mixture in which the components lead to convergence to a 
minimal melting point below that of both components. (2) Shows a binary mixture with a new binary 
phase, in this instance the phase has a lower melting point than the starting components, but 
intermediate and higher melting points are also possible. (3) Displays the thermal behaviour of a solid 
solution with the black line depicting the ideal behaviour and the dashed line highlighting potential 
deviation from ideality.  
As discussed in section 2, at the molecular level there are numerous clear differences between salt 
and cocrystal binding behaviours, but in terms of the binary thermodynamic phase behaviours, salts 
and cocrystals cannot readily be distinguished if organic counter ions are used; inorganic counter 
ions have significantly different thermal behaviours and although follow the same rules, do so on 
different temperature scales. It is the ternary (solution) behaviours that set these phases apart and, 
for salts, represent the most efficient method for screening for new phases. It is common to screen 
for cocrystals thermally and through solution behaviours, however. The utility of both DSC[80] and 
thermal microscopy approaches[81] have been widely discussed. The major problems with screening 
in this way are thermal decomposition of the API, or the second entity, which can erroneously rule out 
potentially useful phases and the time cost of thermal microscopy vs. other approaches. 
 
3.2 Solution properties of salts 
The details of the physical chemistry of salts have been dealt with elsewhere to an excellent 
standard,[1, 82, 83] but are included here to highlight key points in salt design. To make a salt an 
ionisable group in the API molecule, a counter ion for it to interact with and a solubilised population of 
both components are required, which can interact to form a solid salt. A molecule’s aqueous solubility 
as a function of pH dictates whether a compound will form salts and, if they form, what their 
properties might be. The charged species of the API and counter ion usually have greater 
interactions with water and therefore higher solubility. A gap of around 2 pH units, from the pKa 
towards charge, is seen to lead to exponentially greater solubility; this can be seen in Figure 16.  In 
practice the continued exponential increase in the size of the charged species’ population is stopped 
by the solubility of the salt, which will be discussed below.  
A + B
0.5 0.75 10 0.250.5 0.75 10 0.250.5 0.75 10 0.25
Conglomerate/
eutectic
Binary mixture with 
multiple eutectic points
Solid solution
T
e
m
p
e
ra
tu
re
T
e
m
p
e
ra
tu
re
T
e
m
p
e
ra
tu
re
Mol fraction of A Mol fraction of A Mol fraction of A
(1) (2) (3)
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
The classic rule of thumb is that a pKa differential of 3 pH units is required for salt formation between 
an acid and a base, although a 2 pH unit separation is also often quoted. A study by Brittain has 
shown the basis of this rule, by studying salts in relation to their equilibrium constant.[84] This rule is 
based on the solubility enhancement which is seen once both species are charged in solution. A 3 pH 
unit separation between the pKa values of the given molecules should maximise the possibility of salt 
formation and reduce the chance of disproportionation in pure water. This is because at the 
intermediate pH both molecules have large solubilised populations and therefore opportunity to 
interact to form a salt. Many examples exist where salts can form with a smaller pKa separation 
however[85, 86] and the picture is complicated where multiple ionisable groups are available in a 
given molecule.[83, 87] 
The optimal method for the screening for salts and cocrystals has been the focus of many articles 
over the last decade.[88-90] Salts have long been screened for by utilisation of the solubility product 
Ksp (Equation 1). This constant is defined by the concentrations of the charged species in solution 
and is a constant for a given salt (tosylate, maleate etc.) which is based on the salt’s equilibrium 
solubility; not the intrinsic (uncharged) equilibrium solubility of the free API.  
𝐾𝑠𝑝 =  [𝐷𝑟𝑢𝑔 𝑖𝑜𝑛][𝑆𝑎𝑙𝑡 𝑐𝑜𝑢𝑛𝑡𝑒𝑟𝑖𝑜𝑛]        (1) 
Ksp is intrinsically linked to the concept of pHmax. This is the pH of maximal salt solubility; it is also the 
pH point which determines the equilibrium solid product obtained from solution. In the case of a base, 
at pH values below the pHmax it is accepted that the resultant solid will be the desired salt, at pH 
values above it the free base will be the precipitation ‘solubility’ product of a supersaturated solution. 
This factor also has significant impact on the likely stability of a salt once it has been produced,[84, 
85] so pHmax has value in understanding both the production and utility of salts. Figure 17 graphically 
depicts how a change in the salt can alter the Ksp and pHmax. Here it can be seen that a change from 
the tosylate salt (C) to the HCl salt (A) leads to a 95% shift in the Ksp value; where the Ksp of salt C is 
5% of the value of the Ksp of salt A. Such shifts have significant implications on the formation and 
stability of a salt, this is especially pertinent in weak bases which represent many pharmaceutical 
small molecules.  
 
Figure 17. Solubility diagram of salts of a weak base having a low intrinsic solubility and pKa of 5.0, 
with salt forms: (a) hydrochloride: pKa -6.0, (b) sulphate: pKa -3.0,1.92, and (c) tosylate: pKa -1.34, 
having solubility of 200, 50, and 10 (weight per volume), respectively (adapted from reference[85]). 
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As the Ksp is a constant, re-arrangement of equation 1 shows that an excess of counter ion in solution 
(for a given salt) will drive the formation of the solid of the salt (Equation 2).This has been the 
underpinning factor for salt screening strategies for some time i.e. an excess of counter ion added to 
a solution of drug in a solvent.[36] It is also the reason that the common ion effect is seen in HCl 
salts. In the common ion effect excess HCl present in stomach acid reduces the solubility of the salt, 
which will affect its utility in vivo.[91] This can have a significant effect on the dissolution, and 
subsequent utility, of HCl salts.[82] 
[𝐷𝑟𝑢𝑔 𝑖𝑜𝑛] =  
𝐾𝑠𝑝
[𝑆𝑎𝑙𝑡 𝑐𝑜𝑢𝑛𝑡𝑒𝑟𝑖𝑜𝑛]
         (2) 
 
Figure 17 also shows a shift in the pH of maximal solubility (pHmax) from pH 4 to pH 2.7 when 
changing from salt C to salt A. This can be determined from Equation 3. It is important to be aware of 
this, as when in solution above the pHmax (> pH 2.8 in this instance) the free base could precipitate.  
𝑝𝐻𝑚𝑎𝑥 = 𝑝𝐾𝑎 + log
[𝐵]𝑠
√𝐾𝑠𝑝
          (3) 
 
It should be noted that only at pHmax can crystalline solids of both the free base/acid (drug) and the 
salt co-exist. This means that at this invariant point the solubilities for the free ‘species’ and the salt 
are equivalent and is the basis for the ability to derive equation 3 where base concentration ([B]s) is 
directly related to Ksp.[82] [B]s is also called the intrinsic solubility (So) in the literature and is the 
solubility of the uncharged species.  So can be experimentally determined (for a base) at pH values 
well above the pKa, and remains an invariant amount of a solution population at all pH values 
because the population of charged species rises with pH shifts. The relationship between the factors 
in equation 3 has led to derivation of the following outcomes:  
A) An increase in pKa, of the free base, by one pH unit will lead to an increase in pHmax by one 
unit too. To achieve this practically needs a modification to the drug molecule in question.  
B) An increase in the intrinsic solubility of the base by one order of magnitude increases the 
pHmax by one unit. Again this requires API modification to make it a useful strategy.  
C) A decrease in salt solubility (Ksp) by one order of magnitude increases pHmax by one unit. This 
property can be altered by the selection of differing counter ions and if a salt forms would lead 
to a greater pH range under which it is stable, but at the cost of lower solubility.  
The importance of these factors on the design of salts is that if the pKa of a base is low and/or that 
the solubility of the API is low then the chances of salt disproportionation are high because the pH 
range under which the salt is the equilibrium solid species is limited. Conversely more water soluble 
drugs which have stronger bases are preferable for the development of stable salts. Similar, though 
inverse, relationships exist for acidic species. This can be seen in Figure 18, which compiles data on 
marketed (basic) small molecule drugs to 2011, comparing their pKa against the selected salt counter 
ion. Although this data does not describe a direct causal relationship, it is apparent that production of 
stable pharmaceutical salts of API molecules with a pKa which is less than 5 is difficult (as it happens 
infrequently) and in such instances (pKa <5) it would be rational to consider cocrystals as an 
alternative physical form.  
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Figure 18. Graph depicting the pKa of the strongest base within an API versus the free base or salt 
form chosen for formulation in the product (Reproduced with permission from reference[85]). 
 
Therefore when designing salts, a significant gap (ideally >2 pH units) between the pKa of the drug 
molecule and the salt pHmax is advisable. This 2 pH unit separation maximises the chance of a high 
concentration of both species of ions in solution and the best opportunity of salt formation. When 
considering weak bases, choosing a large pKa to pHmax separation may increase the chances of 
disproportionation however. This effect is due to reducing the pH range over which the salt is the 
stable solid product, so a balance should be struck between solubility and stability. Ideally counter 
ions should also be non-toxic[1] and Stahl[90] organises salt formers into three categories (class I, II 
and III). These go from ubiquitous counter ions which are commonly found in vivo (class I) to those 
which are not found naturally occurring and are infrequently used (class III). Examples of class I salt 
forming counter ions would be within hydrochloride and sodium salts. Class II salts tend to involve 
counter ions that are of vegetable origin and are found in foods, such as malonic acid. Malonic acid is 
toxic, but half of the lethal oral dose (the LD50) is 4 g in mice[90] i.e. an 8 g dose would be lethal to a 
mouse, but would represent eating around half its bodyweight (approx. 20 g). Third class salts are 
those which may be used to solve a particular problem, they are infrequently used and include 
counter ions such as cyclamic acid, for which there are safety concerns. Finally consideration should 
also be given to the likelihood of sublimation of the counter ion as in a number of systems this has led 
to disproportionation of the salt on storage.[92, 93] This same problem is feasible, although as yet 
unreported, within cocrystal systems.  
 
3.3 Solution properties of uncharged cocrystals 
Like salts, the phase behaviour in cocrystal systems has been dealt with elsewhere in a number of 
high quality papers and reviews.[12, 87, 94-98] There is also a body of excellent work based on the 
computational screening of cocrystals.[99-107] Discussion of this is beyond the scope of this review, 
but such approaches have been shown to be effective and improve the efficiency of experimental 
cocrystal screening.  
Cocrystal thermodynamic behaviours differ from salts as they do not require a charged species in 
order to be able to form, so their solution phase behaviours are commonly represented within 
isothermal ternary phase diagrams. These represent the three chemical constituents (A + B + 
solvent) and describe the interplay of phases as the thermodynamically stable result of their mixing at 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
differing compositions (Figure 19). If a cocrystal exists such diagrams describe a minimum of four 
phases; the liquid, the crystalline API, the crystalline coformer and the cocrystal. If multiple cocrystals 
exist the number of phases described within the phase diagram would increase.  
The Gibbs rule of phases enables understanding of the construction of the phase diagram:  
𝑣 = 𝑐 + 2 − 𝜑           (4) 
𝑣 = variance i.e. the number of variables that can change at a given composition c = number of 
independent components, this is two in the diagram shown. This is because the cocrystal is a product 
of the interaction between the API and coformer, meaning they are not independent of each other. So 
in the diagram shown the independent components are solvent and the solids (API + coformer = 
cocrystal). The variable 𝜑 is the number of phases, which in this example is a maximum of four. It is 
evident from application of equation (4) that only three phases can exist concurrently at a fixed 
temperature, however. As the number two in the equation refers to the external parameters of 
temperature and pressure, this variable is reduced to one in an isothermal diagram. It has been 
common in the cocrystal literature to date to express thermodynamic data in an isothermal diagram. 
These diagrams show the thermodynamic product of a given composition and are constructed by 
application of the phase rule.   
 
  
Figure 19. A ternary phase diagram displaying the interplay between API, coformer and solvent. 
Axes run from 100% (label) to 0% (other component) in mass ratio.  
In Figure 19 only zone 6 is able to display significant compositional variance as only one of the 
independent components is represented (solvent). All other phases are connected as the cocrystal is 
the product of the interaction between API and coformer, so have fewer degrees of freedom. Zone 6 
is therefore able to interact at various compositions with three phases (1= cocrystal, 2= API, and 3 = 
coformer respectively). Red circles highlight where the composition of the liquid phase is invariant 
due to application of the phase rule (i.e. 3 phases meet). These are also called the eutectic points 
and represent the compositions where the solid products of the interaction between the components 
are pure API (right circle as an example) and cocrystal in equilibrium with a fixed liquid composition. 
These eutectics are comparable to the salt pHmax, i.e. they are invariant compositions where solids of 
binary solid and free base can coexist. Eutectic points are normally joined by ‘tie lines’ to known 
compositions i.e. in a 1:1 cocrystal the 50:50 point between API and coformer and the component in 
questions 100% composition, as in Figure 19. Within the diagram the remaining unknown 
compositions in both zones 2 and 3 are between the eutectic (invariant) point and the pure form 
solubility (API or coformer) i.e. the border between zone 2/3 and zone 6. A comparable relationship 
exists between both eutectic points and the ‘central zone’ (zone 1) and solvent (zone 6). Within the 
compositional points that link these three thermodynamic outcomes (i.e. the product of zones: 1-6, 2-
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6, 3-6), the two phases which are present are solid and solvent. Therefore the compositions at these 
phase borders are important as they represent the thermodynamic solubility of the mixture in 
question. The final compositions represented by an isothermal diagram are in zones 4/5. Here three 
phases are present and pure solid API and cocrystal (as a mixture) are in equilibrium with a fixed 
composition of liquid (the eutectic point).  
Ternary phase diagrams have significant utility in designing crystallisation processes and also form 
the basis for many screening processes.[108-112] For both screening and crystallisation approaches 
it is very important to select the appropriate solvent. This is because if one of the components shows 
no solubility in the solvent, significant skew can be seen in the phase diagrams.[113] Ainouz et al. 
determined a number of phase behaviours as the solubility was reduced (Figure 20). From these 
behaviours they deduced that with decreasing API solubility the zone in which a cocrystal could be 
obtained first shrank and then disappeared with a shift from roughly equivalent solubility (1/1.2), to 
1/3 and around 1/10 of the solubility, respectively. Figure 20 also displays the fact that where fewer 
solvent molecules will interact with each API molecule, i.e. it is less soluble, the ratio of solvent to API 
will shift; with more API to each solvent molecule. To circumnavigate these problems they suggested 
the following: the solubility of the API and coformers should be measured in a set of solvents 
(although solubility prediction across solvents, if one solubility is known, has subsequently improved 
to a robust standard.[105, 114]) and the solvent displaying the best solubility for both components 
should be chosen. The skew in such phase diagrams also gives an insight into why solvent drop 
grinding may find cocrystal phases which cannot be detected by other means.[9, 113] 
 
Figure 20. Showing a (a) symmetrical, (b) skewed and then (c) absent cocrystal region as the 
solubility of the API is reduced from (a)>(b)>(c). Reproduced with permission from reference.[113]  
A further key piece of learning that can be derived from investigation of thermodynamic cocrystal 
relationships is associated with the solubility of the cocrystal phases.[94] Good and Rodríguez-
Hornedo investigated the equilibrium of a cocrystal with the solution phase, using chemical potential 
() to describe this relationship.  
𝜇𝐴𝛼𝐵𝛽
𝑠𝑜𝑙𝑖𝑑 = 𝛼(𝜇𝐴
𝑠𝑜𝑙𝑛) + 𝛽(𝜇𝐴
𝑠𝑜𝑙𝑛)         (5) 
Equation 5 describes the fact that the solubility of the cocrystal (solid AB) is measurable, from a 
thermodynamic perspective, when solid AB is in equilibrium with A and B in solution. Analysis of the 
phase diagram shows that at the transition concentration (phase border) the solution is saturated with 
A (which is API in this example). At this border the chemical potential of the solid drug and drug in 
solution are equal, because they are at equilibrium.  
𝜇𝐴
𝑠𝑜𝑙𝑛 =  𝜇𝐴
𝑠𝑜𝑙𝑖𝑑           (6) 
When considering one uncharged drug substance the chemical potential of the solid (𝜇𝐴
𝑠𝑜𝑙𝑖𝑑) remains 
constant across phase space and it is possible to substitute the chemical potential of drug in solution 
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(𝜇𝐴
𝑠𝑜𝑙𝑛) for the saturated concentration of the API (C). This means that the relationship of cocrystal 
solubility can be simplified to the following:  
𝜇𝐴𝛼𝐵𝛽
𝑠𝑜𝑙𝑖𝑑 = 𝛽(𝜇𝐴
𝑠𝑜𝑙𝑛) + 𝐶          (7) 
It is clear from this relationship that the chemical potential of the cocrystal is proportional to that of the 
coformer i.e. a more soluble coformer will lead to a proportionally more soluble cocrystal. Therefore 
ternary phase diagrams show two key cocrystal behaviours which can be used for effective cocrystal 
design: 
1. A more soluble coformer will lead to a more soluble cocrystal at equilibrium.  
2. A highly skewed solubility profile (API to coformer) may lead to disassociation once a solid is 
placed in a non-equilibrium environment, such as the dosing of a drug in vivo.  
With respect to using phase diagrams for screening for new cocrystals, another consideration is the 
way in which to conduct the search. Solvent drop grinding[115-117] and reaction crystallisation[108] 
stand out as the ‘go to’ initial methods and have been seen to find more phases than other methods 
in a number of systems. Other methods, including computational screening, have also been usefully 
applied to additional learning about the intermolecular interactions and phase behaviour of the 
system.[118] 
 
3.4 Solution properties of ionic cocrystals 
It is possible for an API compound which forms a cocrystal to have some degree of weak ionic 
character within its structure. It is entirely possible for the coformer to also possess an ionisable 
group. This leads to additional complexity with respect to cocrystal solubility behaviours, but also 
enables the potential to tailor cocrystal release to different regions of the GI tract based on charge, as 
acidic coformers will be more soluble in the more basic environment of the small intestine (~pH 6.5). A 
theoretical study by Bethune et al. [87] showed the pH solubility dependence of an acidic coformer 
against an API with no ionisable group (Figure 21). As the API has no ionisable group its 
concentration remains constant across the pH range, whereas the coformer’s changes. In the Figure 
the constant API concentration (yellow plane) is intersected by the variable (pH dependent solubility) 
transition concentration of the coformer. This shows that at increased pH the coformer solubility 
(displayed by the blue surface) rises. Akin to the common ion effect, increased concentration of the 
coformer will drive down the cocrystal solubility and cause precipitation of the cocrystal as the 
solubility product (the thermodynamically stable product at a given composition). Further work in this 
area has increased the prediction landscape to include temperature as well as pH behaviour.[119-
121] This work has also provided additional evidence that changes in pH can affect the solution 
stability of cocrystals, with the lone parent phases of weakly acid API molecules being the product of 
the thermodynamic interaction at low pH and cocrystals at higher pH (nicotinamide/succinic acid 
system) i.e. when used orally, in the acidic stomach an ‘acidic’ cocrystal will disassociate like a weak 
salt.  
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Figure 21. Displaying the theoretical interplay between API concentration [R]t, coformer concentration 
[A]t and pH for a non-ionic API and a monoprotic acid coformer (reproduced with permission from 
reference[87]).  
This work has been expanded by the addition of consideration of the solubilisation of surfactants 
within biorelevant media such as Fasted State Simulated Intestinal Fluid (Fassif) and Fed state 
Simulated Intestinal Fluid (Fessif).[95] This work concluded that not all cocrystals that have shown a 
solubility improvement in pure water have a solubility that is higher than that of the parent API in 
‘solubilising’ media.  Equation 8 displays the link between ‘solubilised’ and ‘pure’ aqueous solubility 
behaviour that this work determined.  
𝑆𝑅𝑐𝑜𝑐𝑟𝑦𝑠𝑡𝑎𝑙 = √𝑆𝑅𝑑𝑟𝑢𝑔          (8) 
Here the solubility ratio (SR) is defined as the total solubility (ST) in surfactant media (all charged and 
uncharged species of drug, coformer and surfactant) divided by the aqueous solubility of the cocrystal 
or parent API at a given pH.  
(
𝑆𝑇
𝑆𝑎𝑞
)
cocrystal
 = √(
𝑆𝑇
𝑆𝑎𝑞
)
drug
           (9) 
Due to the common driver for cocrystal selection being solubility enhancement of the API, the drug 
molecule is often more lipophilic than the hydrophilic coformer and is surfactant solubilised to a 
greater extent.  
The implications of these behaviours, like with weak salts, are that within formulations pH should be 
monitored. This is because pH changes within the formulation may lead to disassociation of the 
cocrystal to the starting components. In testing conducted to predict in vivo cocrystal behaviour pH 
speciation should also be considered, as it may lead to a decreased solubility. Solubility in biorelevant 
media should also always be considered as a more water soluble cocrystal may not carry an in vivo 
advantage. These are thermodynamic behaviours, however. Where disassociation of a cocrystal is 
predicted it may be possible, through a kinetically stabilised phase, to maintain the benefits through 
the ‘spring and parachute effect’ (discussed in section 3.6). Given the choice, however, it is less risky 
to target optimal performance improvements from a thermodynamic perspective.  
 
3.5 Implications of second component choice on physical properties 
Appropriate screening methods for cocrystals were the focus of much of the early work within the 
cocrystal literature. Due to the uncertainty in optimal screening parameters that the work addressed, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
it is unsurprising that little attention was paid to consideration of the final use of the resultant phases. 
Within the broader literature there have now been major advances in the use of individual cocrystals, 
however. These will be discussed in the following sections.  
 
3.5.1 Melting point 
The melting point of a phase is an invaluable tool in determining its physical stability with respect to a 
given manufacturing route as many processes, such as milling and roller compaction (unless 
temperature regulated) will lead to an increase in the temperature experienced by the API. Other 
routes such as hot melt extrusion specifically require the mixture to melt in order for appropriate 
processing to occur.[10, 122, 123]  
It is common for the interaction between coformer and API to lead to a cocrystal of intermediate 
melting point. In some cases, however, a cocrystal may have a higher or lower melting point than that 
either of the pure components. Schultheiss and Newman reviewed this behaviour thoroughly in 2009 
and determined that 51% of cocrystals possess a melting point between those of the starting 
components, 39% were lower than either component, 6% were higher and 4% (2/50) were the same. 
[12] This analysis did not take stoichiometry and hydration into account and was also undertaken on a 
small dataset, but it is clear that melting point can be manipulated via cocrystallisation. For example, 
the melting point of AMG 517[124] was tailored to some degree by use of cocrystals (Figure 22). It is 
therefore viable to tune the melting point of a cocrystal to a required process, if appropriate cocrystal 
phases can be prepared for a given API.  
 
 
Figure 22. AMG 517 1:1 cocrystals and their melting points vs. coformer, displaying a degree of 
melting point tuning. With permission from reference.[124] 
 
3.5.2 Hygroscopicity 
When materials are stored their behaviour with respect to moisture can have significant impact on 
their utility and long term stability,[93] both from a chemical and physical stability standpoint. As 
discussed in section 2 salts can display poor resistance to hydration, cocrystals present a difference 
here. Indeed one of the first purported benefits of cocrystals, was seen in a system where the 
resistance of caffeine to hydration was improved.[5] Other cocrystals have also been seen to reduce 
hygroscopicity when compared to the parent phases alone or in physical mixtures.[13] Resistance to 
hydration is a consistent behaviour in which cocrystals show a significant advantage over salts, but 
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not always the parent API.[125] It has also been shown that coformers can lead to deliquescence and 
subsequent cocrystal formation,[126, 127] so the composition of a formulation should be considered if 
the excipients used are hygroscopic and have the potential to form cocrystals. Hydration to 
alternative, less soluble, crystalline states has been shown in the isoniazid·4-hydroxybenzoic acid 
system,[30] so hydration behaviour should always be monitored throughout development.  
3.5.3 Compression behaviours 
Poor compression is a problem in pharmaceuticals as both roller compaction, to form granules (which 
in turn improve powder flow and mixing), as well as tabletting require the compression and 
compaction of materials into a more dense state. In this context compressibility is the potential of a 
powder to decrease in volume when under pressure, whereas compactibility describes the ability to 
be compressed into a tablet with a reproducible, and desired, tensile strength. Understanding of the 
synergistic effects of the material properties of the drug and excipients is essential for appropriate 
design of a formulation.[128-131] It is entirely possible to formulate around poor compression 
behaviour by use of excipients to ‘drown out’ the API properties. Where high dose or high drug 
loading is needed, within a dosage unit, the compression and compaction behaviour of the API 
becomes more important. Cocrystal compression behaviours have not been extensively studied to 
date, but a number of examples exist in which cocrystal phases have shown improvements in 
tabletting performance. [13, 132, 133] Comparison of two carbamazepine systems has been 
undertaken.[134, 135] In both the carbamazepine·nicotinamide and carbamazepine·saccharin 
systems an increase in tensile strength for a given pressure was seen with a proportional increase at 
1500 lb/cm
3
 of 2.00 and 2.19 times, respectively. These cocrystals were also seen to have a lower 
intrinsic dissolution rate than the compacts of the API molecules, an observation attributed to the 
inverse relationship between higher tensile strength and lower dissolution rate. In other work, analysis 
of slip planes within the cocrystal structures has been completed to determine their mechanical 
effect.[136-139] Notable in analysis of these systems are the structural analogues of vanillin in 
combination with 6-chloro-2,4-dinitro aniline. Here it was seen that slip planes in the ethylene diamine 
cocrystal led to higher elasticity. The most extreme example of elastic cocrystal behaviour was seen 
in the caffeine·4-chloro-3-nitrobenzoic acid methanol solvate.[140] Single crystals of this material can 
recover elastically from deformation into a near complete loop, as displayed in Figure 23. The 
desolvated structure displayed no such behaviour, although structural collapse was not seen on the 
loss of solvent,[141] and the elasticity was attributed to the weak dispersive interactions in all three 
lattice directions. In general it would appear to be prudent to explore slip planes and weak interactions 
within molecular crystals to modify compression behaviour and the ability to predict such behaviour 
would be advantageous.  
 
Figure 23. (a) to (g) initial compression and return to initial crystal structure in single crystals of the 
caffeine : 4-chloro-3-nitrobenzoic acid methanol solvate. (h) to (i) compression beyond breaking point.  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
3.5.4 Coamorphous materials 
 
The amorphous state is useful in pharmaceuticals as it represents a mechanism by which the 
solubility can be improved without the need for alterations to be made to the API molecule.[142] The 
main caveat to amorphous solubilisation is the lack of physical stability that it brings. This is often 
overcome by use of polymeric materials with high glass transition temperatures to reduce the 
likelihood of crystallisation.[143-145] This comes at a cost with respect to drug loading though, i.e. 
each capsule can only contain a small amount of drug because of the large amount of stabilising 
polymer required. As a result molecular level amorphous dispersion of an API using small molecule 
coformers offers a distinct advantage. Both coamorphous materials and amorphous salts[146-148] 
have been seen to be useful in stabilising API molecules and improving their solubility, with an 
excellent review of coamorphous materials published recently.[149] Neither phase has yet received 
the degree of research effort seen by stabilisation with polymers and this may in part be due to the 
inherently comparable glass transition temperatures (Tg’s) within small organic molecules, as 
compared to the high Tg’s seen in polymers. Application of the Gordon-Taylor equation,[150] displays 
the negative effect of this behaviour.   
 
𝑇𝑔12 =
𝑤1𝑇𝑔1+𝐾𝑤2𝑇𝑔2
𝑤1𝐾𝑤2
          (10) 
 
Here Tg12 is the glass transition of the amorphous mixture and Tg1 and Tg2 are the glass transition 
temperatures within the individual components, w1 and w2 are the weight fractions of the components 
present and K is a constant.  Therefore if a polymer with a high Tg is used then the Tg of a mixture will 
approach this high Tg value as weight fraction increases, as the constant (K) is usually positive. It 
follows that the fact that small molecules have generally comparable glass transition temperatures 
may be halting scientific progress in this area. Despite the lack of Tg modification (and subsequent 
anti-plasticisation) significant increases in stability, and decreases in molecular mobility, have been 
seen in these phases through increased molecular level interactions.[151-153] Indeed the potential to 
predict these interactions has been explored using computational pairwise affinity calculations.[154] 
Amorphous salts cannot always be readily be defined by the Gordon Taylor relationship, as it is 
impractical to measure the Tg of inorganic counter ions. A study with amorphous indomethacin by 
Tong et al. showed the change in Tg could be mapped against ionic radius of the counter ion.[147] In 
this study cation charge was mapped against Tg in a series of monovalent salts. Increases in ionic 
radius led to an inverse dependence in Tg, shifting from the highest Tg in the lithium salt to the lowest 
in the caesium salt 139 °C to 69 °C, Li
+
>Na
+
>K
+
>Rb
+
 > Cs
+
. Since the strongest electrostatic 
interaction led to the highest Tg, it was proposed that the sodium salt should be selected, as lithium 
salts are toxic. Evidence to date would suggest the stability of coamorphous phases is highly moisture 
content dependent,[149, 154, 155] and that this is also a problem with respect to amorphous salts. 
None the less, these phases are under studied and represent significant potential for advances in 
small molecule drug delivery if such properties can be controlled by design or formulation.  
 
 
3.6 Implications of the second component on dissolution and pharmacokinetics 
It is evident that manufacturing routes and quality attributes can be altered by salt formation and the 
application of cocrystals. Salt forms have been known to modify the bioavailability of API molecules 
for many years[1] and their behaviours in this respect are well characterised and understood, so will 
not be dealt with here. Cocrystals are less well known from this perspective and have a growing 
evidence base in this regard. As such section 3.6 will deal predominantly with the biopharmaceutical 
implications of cocrystals.  
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3.6.1. Impact on dissolution 
The improvements in in vitro dissolution have been shown in many studies and reviews over the last 
decade for both salts of poorly soluble drug products and cocrystals.[1, 11, 31, 156, 157] Dissolution 
is a method commonly used to determine a relationship between in vitro study and in vivo usefulness 
of a drug product with the rate, extent and profile of the dissolution process being indicative of the 
biopharmaceutical utility of a given phase.[158]  It also represents a key link between kinetic and 
thermodynamic behaviour, as in some instances short term benefits (a ‘spring’) can be enough to 
drive improved in vivo absorption. Sometimes the duration of this spring effect is not sufficient 
however and it is pertinent to seek a nucleation inhibitor or metastable phase which elongates this 
transient concentration increase, often termed a ‘parachute’. A number of the potential dissolution 
outcomes, such as these, have been seen throughout extensive study and are displayed in Figure 24. 
It should be noted that although not displayed in the Figure, one potential option is that the new phase 
has a lower solubility and slower dissolution rate than the parent API, this has been shown in a 
number of studies.[12] Such a delay in dissolution, although not generally the driver for the study of 
new phases of pharmaceutical products, could be used to modify the release of products of highly 
soluble agents and has a great utility in agrochemicals.[159] 
 
   
Figure 24. Depiction of the spring and parachute concept to improve dissolution in poorly soluble 
drugs. The (low solubility) stable polymorph of the free form depicted in green, a spring with no 
parachute, short lived metastable species, depicted in blue, a sustained solution phase depicted in 
orange (left) and the spring and parachute model, depicted in red (right). Adapted from reference 
[157]. 
It is clear from Figure 24 that there are a number of potential options for the dissolution of a cocrystal 
or salt and that they can be compared to select the most appropriate phase for in vivo utility. Indeed a 
comparison of the dissolution data for norfloxacin (a compound which has polymorphs,[160] 
amorphous forms[161], salts and cocrystals[162]) shows the relative benefits of each phase from a 
biopharmaceutical perspective. This should be considered in the context of the fact that no solubility 
data exists for the enantiotropic polymorph of norfloxacin, but previously Hancock and Parks showed 
the solubility difference between polymorphs to be within the region of a maximum of 3 times[142] and 
subsequent study gave further evidence for this.[163] Within norfloxacin it can be seen that the 
advantage of the salt over the uncharged cocrystal is significant (46 times better), but the amorphous 
phase comparable (although undoubtedly superior). A similar circumstance was seen by Almeida and 
co-workers when looking at the relative supersaturation ratios of a number of phases of CRH1, a 
model weak base.[164] Here it was seen that the cocrystal was again comparable to the unformulated 
amorphous phase, but significant improvements in supersaturation were seen when the amorphous 
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form was formulated, but gave further evidence for a maximal value in supersaturation associated 
with formulations.[165] It is within the body where sink conditions, generated by drug absorption, 
enable these differences to be most effectively studied however.  
Table 1. Comparative dissolution data for norfloxacin cocrystal, salts and amorphous dispersions 
Phase Solubility ratio 
Free base 1.00 
Isonicotinamide cocrystal 2.76 
Succinic acid salt 31.42 
Malonic acid salt 18.57 
Maleic acid salt 46.66 
Norfloxacin/PVP (70% / 30%) 3.05 
Norfloxacin/HPC-L (70% / 30%) 3.85 
Norfloxacin/Carbopol (75% /25%) 2.615385 
Norfloxacin/PVP/HPC-L (75% /12.5% /12.5%) 5.307692 
Norfloxacin/PVP/Carbopol (75% /12.5% /12.5%) 2.87 
Norfloxacin/HPC-L/Carbopol (75% /12.5% /12.5%) 3.23 
 
3.7 Basic Pharmacokinetic parameters  
The study of pharmacokinetics (PK) defines how much of an API is in the defined ‘body’ at a certain 
time. To an extent, study of pharmacokinetics is not a useful endeavour without some knowledge of 
the pharmacodynamics (PD) of the given drug. The distinction between these two areas is that 
pharmacodynamics is the study of what the drug does to the body and pharmacokinetics is what the 
body does to the drug. Pharmacodynamics describes the drug’s effect at a given concentration, both 
desired and toxic, and PK describes its absorption, distribution, metabolism and elimination (ADME). 
The study of pharmacokinetics, when combined with pharmacodynamic information, enables 
knowledge of the doses required to yield safe and effective use of a drug. Although there is commonly 
a relationship between dose and response it does not necessarily hold that drug action will be 
concentration dependent as this depends on the pharmacology of the agent under study.  
At its simplest PK is studied through the single compartment model,[166] although very significant 
work has been undertaken, for many years, looking at the compartmental distribution of drugs, both 
empirically and computationally.[167, 168] The single compartment model is where the body is 
considered to be one compartment with drug only going in and coming out of this ‘body’; rather than 
the true biological complexity that this represents. In this, and other models, it is common to take 
samples of blood at fixed times to define the ADME process. Blood, and plasma taken from the body, 
are used as they perfuse other tissues and quickly become homogenous with respect to API 
concentration, therefore can be representative of the body as a single compartment. Once a suitably 
robust assay has been defined it is then possible to determine a concentration vs. time relationship for 
a given drug and, in the context of this review, compare different phases and formulations. An 
example PK profile showing the key PK parameters can be seen in Figure 25.  
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Figure 25. A representative oral PK profile showing Cmax, Tmax and AUC (shown in yellow). Half-lives 
for absorption and clearance processes can be calculated by study of the absorption and elimination 
phases (green and red respectively).  
Absorption and elimination phases represent the period of time in which a given process is dominant. 
Both processes can be described by their rate and are usually defined by first order processes 
enabling calculation of a half-life (t1/2). It is more common for a reported t1/2 to describe clearance, 
however. It should be noted that absorption processes will still occur into the elimination phase, but 
will no longer dominate. The time point at which these processes switch dominance is described by 
the Tmax. This also describes the time at which the concentration is at its highest within a given study. 
This parameter can also be usefully applied to calculate the exact Cmax if it is not seen in sampling. 
The Cmax parameter describes the maximum concentration observed in the respective compartment 
(blood in this example) in a given study. This is an essential parameter as it can be combined with 
pharmacodynamic information to determine whether a given dose will be effective or toxic. The area 
under the curve in a time (AUCtime) describes the total amount of drug which has been absorbed into 
the studied compartment over a period of time, and can also be called ‘exposure’. The time period 
associated with the AUC is usually considered to be either for the time of study (e.g. AUC0-12 hours) or 
to infinity (AUC0-). It is important that the time frame is defined to enable objective comparison of 
AUC between studies, as this is used to define differences between an IV dose or alternative 
formulations. When AUC’s are compared, the resultant parameter is presented as a ratio and is the 
bioavailability, usually denoted as F. It should be noted that when preparing studies for PK to 
compare bioavailability, appropriate definition of the formulation which was dosed, to the animal 
species in question, is also essential. Few studies into cocrystal PK to date show content uniformity 
and stability information for the formulation and this brings the validity of the evidence base into 
question. For example very few studies using suspension based formulation have overtly presented 
X-ray data to compare the form of the drug substance with that in the formulation, despite significant 
evidence of the potential for cocrystal disassociation in solution. It is important that future studies 
address this deficiency, especially when viewed in the light of cocrystal solution physical stability.[12] 
 
3.8 Impact of cocrystal parameters on in vivo PK 
Spanning the academic and patent literature there are now a number of studies that display in vivo 
data for the use of cocrystals.[31, 55, 125, 169-191] The dataset is currently small and totals in the 
region of 74 studies at the time of writing (a study in this context comprises a cocrystal dosed to at 
least one animal to determine pharmacokinetic parameters of that crystalline phase). This 
encompasses studies where the number of animals used is between 1 and 6, with the species varying 
across studies, but remaining constant within a given study. It should be noted that the most 
Absorption phase Elimination phase
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commonly used genus was Canis (beagle dog), but Rattus species (Wister and Sprague Dawley rats) 
have also been frequently used. In analysis of these data, studies with multiple doses of the same 
cocrystal or where formulation modifications have been explored were not considered as multiple 
studies. As it is difficult to present a dose adjusted comparison of such data, one data point was taken 
from each of these studies with this consistently associated with the highest delivered dose, i.e. if 
there were multiple doses the Cmax from the highest dose was used. This was done to remove the 
possible effect of formulation additives leading to incomparable clearance parameters, as will be 
discussed later. This was necessary as it is clear from the available data that coformer choice can 
affect drug clearance. In some cases information from the PK profile was captured from published PK 
profiles using a web based XY plotting tool.[192] Such tools are invaluable in the determination of 
published pharmacokinetic data where parameters are not always described coherently across 
multiple datasets e.g. AUC values are presented but not tabulated Cmax information. Some datasets 
were not complete with respect to solubility information (cocrystal vs. parent), where this was the case 
comparison of the ratio of intrinsic dissolution rate (cocrystal vs. parent) was used. Intrinsic dissolution 
rate has previously been described to be a superior measure for in vivo prediction in the early 
development environment.[83] If this was also not available the linear portion (initial time points) of the 
dissolution rate was used as an indicator of solubility ratio (parent API/cocrystal). Where neither 
solubility nor dissolution data were present, for a given phase, the point was omitted from the plot. 
Data for the relationship between cocrystal solubility and Cmax can be seen in Figure 26.  
 
 
Figure 26. Correlation between Log10 in vitro solubility ratio (API/cocrystal) and in vivo Cmax ratio 
(API/cocrystal). Square data markers indicate that dissolution data was used instead of directly 
sourced solubility information. Red markers display points where improved in vitro solubility did not 
translate to in vivo improvement.  
No clear statistical relationship can be drawn from this plot, indeed the maximum in vivo improvement 
(Cmax ratio) seen in a cocrystal is not plotted here as no in vitro solubility information is available.[175] 
Here a cilostazol·4-hydroxybenzoic acid a cocrystal was seen to have a 14.6 times improvement in 
Cmax ratio. Insufficient evidence is available to determine the structural basis of this in vivo 
performance though. The maximum improvement presented in this data is from a 
quercetin·caffeine·methanol solvate.[188] Here it is evident that the inclusion of the solvent molecule 
may be aiding the in vitro solubility and in vivo performance. Sadly the toxicity of methanol would limit 
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this as a planned strategy for dose delivery. It is evident from Figure 26 that if in vitro data show a 
significant increase in aqueous solubility for a given cocrystal, then an increase in Cmax is both 
possible and likely. Shan et al. [175] previously completed a similar analysis of the cocrystal literature 
in an excellent review on the topic and drew the same conclusion. Within this work the authors also 
showed that an increase in Cmax correlates with an increase in AUC. It should be noted however that 
four of the studied systems which displayed a marginal increase (< 20% increase) in in vitro solubility 
vs. the parent API did not convey any in vivo advantage. These systems were lamotrigine: 
nicotinamide (1:1), meloxicam: fumaric acid (2:1), meloxicam: glycolic acid (1:1) and palperidone: 4-
aminobenzoic acid (1:1).[171, 173, 191] In the case of lamotrigine it is possible that conversion to the 
known, less soluble, hydrate phase occurred. In the meloxicam examples the elimination phase of the 
PK profile was not explored within the 4 hour extent of the study, so it is possible that the true Cmax for 
these examples was not realised as the concentration was still rising at the final time point. The 
paliperidone example is within error of being the same as the parent API (97% of parent Cmax ±11% 
variance in results). Combining the overall trend seen in these data with the previous knowledge that 
more soluble coformers tend to increase the solubility of the resultant cocrystal[87, 175] should aid 
the design of phases which improve bioavailability. It is clear that this logic does not always hold true 
however and a number of cases show that caution should be applied when designing cocrystals in 
this fashion. 
With this fact in mind and the knowledge that in vivo bioavailability has long been known to be a 
combination of both permeability and solubility, most notably considered in the BCS classification 
system,[158] it is pertinent to explore permeability effects in cocrystals. Discussion of the implications 
of API permeability and biorelevant solubility have been addressed by a number of authors,[95, 98] 
but discussion of the coformers’ permeability characteristics have not been a significant feature in the 
literature. Therefore it is rational to determine if the permeability of coformers has an in vivo impact. 
Further analysis of the published PK data reveals that there is indeed a relationship between Log P of 
the drug and coformer and improvements in vivo. This can be seen in Figure 27. Here published Log 
P data (Chemspider[193]) and calculated (Marvin[194]) Log P values were used to compare the ratio 
of Log P  (coformer/API) to the in vivo improvement in bioavailability, as determined by an increase in 
Cmax. This is valid due to the linear relationship between AUC and Cmax in cocrystals.[175]  
 
Figure 27. X-Y Scatter plot showing difference in Cmax from the parent (1.0 is parent API Cmax) vs. the 
Log P ratio of the coformer to API. Significant differences in Log P between API:coformer (>± 0.6 
ratio) appear to lead to no Cmax improvement from the parent API.  
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It is evident from this plot that if the rationale for cocrystal production and selection is an improvement 
in PK (in terms of bioavailability) then this is unlikely to be achieved if the ratio of coformer to API Log 
P is significantly greater than ±0.6 (unitless ratio). The lack of improvement when the ratio is large is 
thought to be due to disassociation of the cocrystal in water if one component is much more water 
soluble than the other and correlates with data from in vitro studies.[95] This observation adds weight 
to the caveat that increasing the solubility of the coformer will not always improve dissolution i.e. if the 
Log P difference is large the benefit will not be conveyed to the in vivo state. Significant decreases in 
Cmax are not seen in the data points beyond the ±0.6 cut-off however with the majority of systems 
showing comparable PK to the parent API. So if a non-PK parameter is the driver for cocrystal 
selection e.g. hygroscopicity of the free drug, then it may prove prudent to explore coformers with 
large log P differences to the parent API.   
Sitting within the ±0.6 Log P cut-off without consideration of solubility is no guarantee of Cmax 
improvement. Those systems that show a Cmax ratio of less than 1 (less bioavailable than the parent 
API) are those which had been seen to show decreases in solubility or only modest solubility 
increases in Figure 25. It should also be noted that only 13.5% of the data points sit outside of the  
‘±0.6 Log P’ zone and this highlights the main drawback to this analysis. A comparable dataset has 
previously been compiled and analysed by Shan et al.,[175] with new studies added in the work 
presented here. Shan noted that the literature is still very sparse in this area, with significant numbers 
of the same carboxylic acids used to form cocrystals of mostly BCS class II drugs, so conclusions 
drawn from this data may not be able to be robustly applied across the broader spectrum of API 
chemistry and ionic cocrystals.  
3.9 Future questions for pharmacokinetic design 
A number of studies have looked at the impact of absorption processes when using cocrystals, but 
there have been two studies[172, 188] in which the cocrystal significantly alters the clearance rate of 
the parent API molecule, these were in quercetin and AMG 517 respectively. Most small molecule 
drugs are cleared from the body by first order processes (elimination half-life remains constant),[166] 
so seeing a significant alteration in this parameter is an unusual occurrence. Within the reported 
quercetin cocrystals[188] it was seen that changing the coformer from caffeine to theobromine led to 
an increase in the clearance half-life of the API from 26 minutes to 145 minutes (~ 80% increase). In 
AMG 517[172] increasing the dose of the sorbic acid cocrystal from 10 mg to 500 mg led to a staged 
increase in the clearance rate from 16.5 hours to 23.1 hours (~30% increase). In both cases the 
cocrystals led to increased drug absorption, so it is possible that the increase in the total 
concentration in the body has saturated the clearance route in these systems, moving the process 
away from first order and increasing the clearance half-life. It is also possible however that the 
variation in coformer used, or the increase in the in vivo concentration of the same coformer 
(respectively), led to some degree of liver enzyme inhibition and resulted in longer clearance half-
lives. As it is considered normal for the coformer and API to be independent by the time that 
clearance processes are occurring it is clear from this evidence that some consideration is needed to 
the enzyme inhibition status of the coformer in the design of cocrystals. Consideration of the inhibitor 
status of coformers is pertinent both from the perspective of elimination processes, as discussed 
here, but also absorption processes. This is because there are a number of active cytochrome P450 
enzymes in the gut wall[195] which may be inhibited and lead to increased systemic concentrations of 
the active drug as it is not metabolised in the gut wall. There is clear evidence that some common 
coformers, for example caffeine and vanillin, actively lead to inhibition of the cytochrome P450 
system.[196] In this respect the practice of dosing a physical mixture of the coformer and API[179, 
181, 189] as well as the cocrystal appears prudent, although from the small data set it is uncertain 
whether the coformer being dosed outside the cocrystal affects the absorption of the coformer as well 
as that of the API. Based on this evidence it would seem advisable when developing PK studies for 
higher animal species, if possible to develop a suitable assay, to track the coformer’s pharmacokinetic 
profile and any inhibition effects it may exert. When selecting the final API form considering the 
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additional medicines that a patient is likely to be taking may also avoid the potential of inducing 
unwanted interactions with other therapies.  
4. Conclusions 
From the data which has been examined it is clear that cocrystals can be designed for use in 
pharmaceutical products and can be applied along with salts as part of the form selection toolbox. 
Cocrystals and salts offer a viable method for the improvement of in vivo exposure for poorly soluble 
API molecules, as well as a route to alter their physical behaviours. Consideration of the following 
physicochemical parameters is essential for the effective design of functional cocrystal and salt forms: 
intrinsic solubility of the API, lipophilicity of both components (in the form of Log P) and the pKa of both 
components to assure phase stability. Melting point and glass transition temperature are important 
considerations when contemplating manufacturing routes, but fluctuations up and down in 
temperature (from the melting points of the parent phases) have been seen in cocrystal phases. 
Further to this development approaches which consider the end user (i.e. the patient) at the start of 
the discovery/development cycle are advisable in order to determine effective production routes and 
the potential of drug A to drug B·coformer interactions as early as possible.  
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